Keywords
Coronavirus Infections
Vaccine
Occupational Health
immunoglobulins
How to Cite
Abstract
The emergence of SARS-CoV-2, the virus causing COVID-19, has resulted in a pandemic that has disrupted all sectors of society. Less than a year after the sequencing of the virus’s genome, emergency use authorization for the BNT162b2 vaccine was requested. The aim of this study was to evaluate the response to the BNT162b2-mRNA COVID-19 vaccine in frontline workers from two hospitals in Colombia. Nasopharyngeal swabs were collected for the molecular detection of SARS-CoV-2 using real-time PCR, and blood samples were taken to assess seroconversion using qualitative and quantitative IgA, IgG, and IgM test kits. The study was conducted at a high-complexity healthcare institution in Bucaramanga, Colombia. 245 people were included in the first round and 129 in the second. SARS-CoV-2 molecular tests were conducted by RT-qPCR, and peripheral blood samples were collected to measure IgG, IgM, and IgA. The main outcome was to establish natural infection and the antibody response induced by the vaccine. The entire population was tested at two fixed times with RT-PCR tests and antibody level measurements approximately 4 and 8 months after receiving the second vaccine dose. 62 (25.3%) and 35 (14.3%) participants had a history of positive PCR in the first and second rounds, respectively. All positive cases showed elevated levels of all immunoglobulins, especially IgG. The average concentrations of IgA, IgM, and IgG at 90 days were 1149.5 U/mL (95% CI 828.2-1470.9); 320.3 U/mL (95% CI 218.4-422.3); and 9277.3 U/mL (95% CI 8989.2-9565.3). Frontline healthcare workers showed an adequate response to the BNT162b2 mRNA vaccine.
References
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27):2603–15. http://dx.doi.org/10.1056/NEJMoa2034577
Della Valle P, Fabbri M, Madotto F, Ferrara P, Cozzolino P, Calabretto E, et al. Occupational exposure in the Lombardy region (Italy) to SARS-CoV-2 infection: Results from the MUSTANG-OCCUPATION-COVID-19 study. Int J Environ Res Public Health. 2021; 18 (5):2567. http://dx.doi.org/10.3390/ijerph18052567
Ferrara P, Albano L. COVID-19 and healthcare systems: What should we do next? Public Health. 2020; 185:1–2. http://dx.doi.org/10.1016/j.puhe.2020.05.014
Ministerio de Salud y Protección Social. Vacunación contra COVID-19. Colombia. 2021. https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx. Published 2021. Accessed May 21, 2022.
Colmenares-Mejía CC, Quintero-Lesmes DC, Acosta IS, Suárez DP, Meneses L, Rincón OL, et al. Seroprevalence of SARS-CoV-2 infection among vaccinated health workers and hospital staff. Arch Clin Biomed Res. 2022;06(02). http://dx.doi.org/10.26502/acbr.50170244
Serrano NC, Quintero-Lesmes DC, Colmenares-Mejía CC, Acosta IS, Suárez DP, Meneses L, et al. Infección por SARS-CoV-2 y respuesta de anticuerpos a la vacuna BNT162b2 en trabajadores de la salud de primera línea de atención para COVID-19. Medicina. 2022; 44 (1) 29-37.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. http://dx.doi.org/10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95(103208):103208. http://dx.doi.org/10.1016/j.jbi.2019.103208
Xiao K, Yang H, Liu B, Pang X, Du J, Liu M, et al. Antibodies can last for more than 1 year after SARS-CoV-2 infection: A follow-up study from survivors of COVID-19. Front Med (Lausanne). 2021;8:684864. http://dx.doi.org/10.3389/fmed.2021.684864
Alzaabi AH, Ahmed LA, Rabooy AE, Zaabi AA, Alkaabi M, AlMahmoud F, et al. Longitudinal changes in IgG levels among COVID-19 recovered patients: A prospective cohort study. PLoS One. 2021;16(6):e0251159. http://dx.doi.org/10.1371/journal.pone.0251159
Buonfrate D, Piubelli C, Gobbi F, Martini D, Bertoli G, Ursini T, et al. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Clin Microbiol Infect. 2021;27(12):1845–50. http://dx.doi.org/10.1016/j.cmi.2021.07.024
Ponticelli D, Madotto F, Conti S, Antonazzo IC, Vitale A, Della Ragione G, et al. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Intern Emerg Med. 2021; http://dx.doi.org/10.1007/s11739-021-02857-y
Kelsen SG, Braverman AS, Aksoy MO, Hayman JA, Patel PS, Rajput C, et al. SARS-CoV-2 BNT162b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19 disease. JCI Insight. 2022;7(4). http://dx.doi.org/10.1172/jci.insight.155889
Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10(100208):100208. http://dx.doi.org/10.1016/j.lanepe.2021.100208
Rossi C, Lanuti P, Cicalini I, De Bellis D, Pierdomenico L, Del Boccio P, et al. BNT162b2 mRNA vaccination leads to long-term protection from COVID-19 disease. Vaccines (Basel). 2021;9(10). http://dx.doi.org/10.3390/vaccines9101164
Notarte KI, Guerrero-Arguero I, Velasco JV, Ver AT, Santos de Oliveira MH, Catahay JA, et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol. 2022; http://dx.doi.org/10.1002/jmv.27688
Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6(58): eabi6950. http://dx.doi.org/10.1126/sciimmunol.abi6950
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Norma C. Serrano , Claudia C. Colmenares-Mejía, Paula K. Bautista-Niño, Diana Paola Suárez, Isail Salazar-Acosta, Angie Y. Serrano-García, Ligia Meneses, Olga L. Sopó-Rincón, Doris Cristina Quintero-Lesmes